To the full analysis
Rigel Pharmaceuticals stock: growth
RIGLRigel Pharmaceuticals reported $294.28M in revenue for fiscal 2025, up 64.1% on the prior year, up 22.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
12.1%
per year from 2006 to 2025, per share 14.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 22.1% | 26.1% | 12.1% |
| Revenue per share | 20.5% | 17.5% | 14.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $33.47M | −$37.64M | −$36.75M |
| 2007 | $12.6M | −$74.27M | −$53.14M |
| 2008 | $0 | −$132.35M | −$106.03M |
| 2009 | $750K | −$111.55M | −$102.92M |
| 2010 | $125M | $37.89M | $43.18M |
| 2011 | $4.75M | −$85.97M | −$71.68M |
| 2012 | $2.25M | −$98.84M | −$88.57M |
| 2013 | $7.15M | −$89.03M | −$87.28M |
| 2014 | $8.25M | −$90.91M | −$70.17M |
| 2015 | $28.9M | −$51.46M | −$23.96M |
| 2016 | $20.38M | −$69.22M | −$76.69M |
| 2017 | $4.48M | −$77.99M | −$77.72M |
| 2018 | $44.51M | −$70.48M | −$59.93M |
| 2019 | $59.29M | −$66.55M | −$42.97M |
| 2020 | $108.62M | −$29.74M | −$53.45M |
| 2021 | $149.24M | −$17.91M | $5.25M |
| 2022 | $120.24M | −$58.57M | −$74.21M |
| 2023 | $116.88M | −$25.09M | −$20.74M |
| 2024 | $179.28M | $17.49M | $31.08M |
| 2025 | $294.28M | $367.02M | $75.66M |
Revenue by segment
How Rigel Pharmaceuticals, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Product$232.0M79%
- Contract revenues from collaborations$62.0M21%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Product | $231.98M | 78.8% |
| Contract revenues from collaborations | $62.03M | 21.1% |
| Total revenue | $294.28M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 10 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.